Genetic Immunity is a Phase III clinical stage biotechnology company committed to discovering, developing, manufacturing and commercializing a new class of immunotherapeutic vaccines for the treatment of viral infections, cancers, allergies and rare diseases. The Company’s two distinguished technology platforms are set to revolutionize the treatment of these chronic diseases. Our Langerhans cell targeting nanomedicines are exceptional in both safety and immune modulating activity, boosting specific Th1-type central memory T cells. These Th1 cells are essential to eliminating infected or cancerous cells, and to balancing the immune system in response to allergens.

The Company's lead product candidate, DermaVir, acts to boost the immune system of HIV-infected patients to eliminate infected cells that remain in reservoirs after antiretroviral treatment. Three clinical trials conducted in the EU and US showed that DermaVir immunizations were as safe as placebo and only four sequential treatments were required to reduce HIV infected cells in the blood within 24 weeks.

Genetic Immunity is a wholly owned subsidiary of Power of the Dream Ventures.

To learn more please visit the corporate website of Genetic Immunity, Inc..